美女免费一级视频在线观看

2025 might shape out to be a boon year for pharma, a recent report from Norstella’s Evaluate suggests.

The 2025 Preview Report examines the “biggest movers and shakers” in the biotech and pharma industry each year.

The findings point to an uptick in drug approvals, pharma sales and promising launches in 2025, following the last few post-pandemic downturn years. 

Most notably, the industry is expected to experience the largest rise in pharma product sales since the COVID-19 pandemic, increasing by $82 billion in 2025.

According to Daniel Chancellor, VP of thought leadership at Norstella, there’s “a lot of momentum” with certain products entering a strong growth phase of the lifecycle. 

“And it’s all coinciding at the same time,” he said.

The report found that 71 new drug approvals are expected in 2025 — up from 50 last year. Additionally, combined pharma industry revenues are expected to reach $1 trillion for the first time.

Obesity rises to the top

Unsurprisingly, the obesity market — dominated by major players Novo Nordisk and Eli Lilly — is driving much of this momentum. The market is expected to grow significantly in 2025 and surpass oncology on the leaderboard.

The report identified what it expects to be the top-selling 10 drugs each year.

For 2025, four of the top six are weight loss drugs. Novo Nordisk’s semaglutide (Ozempic and Wegovy) take the cake, followed by Lilly’s tirzapetide (Mounjaro and Zepbound).

Semaglutide and tirzapetide are expected to generate more than $70 billion in combined sales this year, the report noted. In addition, Lilly’s Zepbound sales are expected to double in 2025 to $11.3 billion.

Among the report’s top 10 biggest drugmakers by prescription sales, Lilly catapulted to the fourth position in 2025, after finishing in 11th place in 2024. 

Still, the top three drugmakers in prescription sales remain Roche, Merck and AbbVie.

“It is almost inevitable that Lilly and Novo will climb further up these rankings in subsequent years,” the authors wrote. “For Novo and Lilly, one of their main priorities in 2025 will be keeping up with demand, and meeting expectations of both patients and investors.”

Outside of obesity drugs, Merck’s blockbuster cancer drug, Keytruda, followed by Sanofi’s Dupixent and AbbVie’s Skyrizi, rose to the top of the forecast.

Even as Merck faces a patent cliff for Keytruda in 2028, 2025 is expected to be the drug’s peak sales year.

The report also highlighted Daiichi Sankyo’s and AstraZeneca’s antibody-drug conjugate (ADC) Enhertu as one of the fastest growing drugs in the coming year, noting it was “leading a new wave of agents to emerge in this modality,” thanks to its impressive efficacy in breast and lung cancers.

Obesity ‘not the only story’

Even as obesity dominates this year, several other therapeutic areas are seeing significant growth drivers in 2025 as well, Chancellor said, with oncology still at the top.

“Oncology isn’t necessarily the story of any one drug in particular, but rather this huge cumulative momentum of many drugs,” Chancellor explained. “There’s innovation in new modalities — whether that’s in ADCs, in radiopharmaceuticals, bispecific antibodies or cell therapies — that’s still propelling oncology at double-digit growth rates.”

In immunology, Chancellor highlighted Dupixent’s ongoing success as well as two of AbbVie’s drugs: Skyrizi and Rinvoq.

“These are all products with incredible momentum that were launched several years ago, but have continued to accrue new indications across the spectrum of immunology. They’re in that fast ramp growth phase of their drug life cycle,” Chancellor said.

He also expects that while neurology may not get peak attention in 2025, it will continue to garner interest in the longer-term, including in drugs for schizophrenia, multiple sclerosis and Alzheimer’s disease.

“The temptation is to think that all of these dynamics and new records being set have been driven by the obesity products — but it’s obesity plus a lot of other momentum in the pipeline,” Chancellor said. “It isn’t just ‘the obesity story.’”

Biggest drug launches to watch

One drug Chancellor said he’ll be keeping an eye on is Vertex Pharmaceuticals’ newly-approved cystic fibrosis treatment, Alyftrek, which snagged a Food and Drug Administration (FDA) greenlight in December.

The once-daily triple therapy is expected to be a “surefire success” because it’s building upon a portfolio of CFTR-modulated specific fibrosis therapies that have already proven their efficacy and safety, Chancellor explained. 

Alyftrek is expected to reach $8 billion in sales by the end of the decade.

Vertex is also moving forward on its non-opioid pain drug, suzetrigine, which would be the first novel pain treatment to enter the market in decades, if approved. 

Late last year, Vertex unveiled new data on suzetrigine showing it reduced pain compared to baseline, but not statistically more than placebo.

While expectations may have dropped since the latest data readout, Chancellor noted the drug is still garnering excitement as a novel pain mechanism, and that the data from the most recent trial doesn’t discredit it entirely.

The report also listed Daiichi Sankyo and AstraZeneca’s ADCs, datopotamab and deruxtecan, as well as Sanofi’s tolebrutinib and GSK’s depemokimab, as potential drug launches to watch this year.

Finally, Novo Nordisk’s Cagrisema — a next-generation obesity drug the pharma giant is developing — will be closely watched as number one on the list of valuable R&D projects the report identified.

In December, Novo rolled out new data on Cagrisema that found the drug resulted in 23% weight loss — but it was lower than industry expectations, with some deeming them disappointing. Still, Novo plans to submit the drug for regulatory approval this year.

“The huge clinical trial readout led to a strong readjustment in people’s valuations of Novo Nordisk,” Chancellor explained. “Maybe the reaction was overdone, maybe it wasn’t — but certainly Cagrisema is looking like a strong contender to becoming a next-generation obesity drug and improving upon Novo’s initial offerings.”

Other promising R&D projects to watch, the report found, include Lilly’s next-generation GLP-1 retatrutide, Amgen’s obesity and diabetes drug MariTide, as well as Immunovant and Roivant’s myasthenia gravis products IMVT-1402 and batoclimab, respectively.

“As a collective, the pipeline should be pretty productive this year, and the commercial value of these drugs as well is pretty good,” Chancellor added. “So it’s a promising year for the class of ‘25.”

A busier year for dealmaking awaits

Much remains to be seen on how the Trump administration — and the people chosen to fill public health positions — will impact the pharma landscape in 2025, from mergers and acquisitions (M&A) to regulatory approvals.

“There’s a lot of speculation out there, and it’s exactly that — speculation,” he said.

Still, Chancellor noted that the consensus suggests that we may be seeing more acquisitions this year, though he believes the industry would see more acquisitions regardless of who won the presidency.

“Last year was a quiet year for dealmaking,” he explained. “Large pharma companies generate a lot of cash each year, and last year they didn’t deploy much of it on acquisitions, which means there is even more for this year to deploy. After a down year, we’re probably going to see an up year anyway.”

Chancellor added that the industry will have a better sense of what pharma M&A will look like in 2025 after the J.P. Morgan  conference next week, which helps set the tone for the year.